Royal Bank of Canada’s Acrivon Therapeutics ACRV Stock Holding History

Royal Bank of Canada’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Sell	25 -1,686	-99%	-$2.94K	﹤0.01%	7044
2025 Q4	$4K	Buy	1,711 +763	+80%	+$1.66K	﹤0.01%	6743
2025 Q3	$2K	Buy	948 +917	+2,958%	+$1.29K	﹤0.01%	6853
2025 Q2	$0	Sell	31 -818	-96%	-$1.12K	﹤0.01%	6980
2025 Q1	$2K	Sell	849 -789	-48%	-$4.25K	﹤0.01%	6544
2024 Q4	$10K	Buy	1,638 +361	+28%	+$2.62K	﹤0.01%	6338
2024 Q3	$9K	Buy	1,277 +161	+14%	+$1.27K	﹤0.01%	6352
2024 Q2	$6K	Buy	1,116 +838	+301%	+$6.75K	﹤0.01%	6470
2024 Q1	$2K	Sell	278 -2,210	-89%	-$10.3K	﹤0.01%	6643
2023 Q4	$12K	Buy	2,488 +927	+59%	+$4.9K	﹤0.01%	6445
2023 Q3	$15K	Buy	1,561 +654	+72%	+$7.56K	﹤0.01%	6270
2023 Q2	$12K	Buy	907 +242	+36%	+$2.93K	﹤0.01%	6398
2023 Q1	$8K	Buy	+665	New	+$11.2K	﹤0.01%	6388

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's ACRV Position: Q1 2026 in Review

Royal Bank of Canada reduced its Acrivon Therapeutics (ACRV) stake by 99% in Q1 2026, selling an estimated $2.94K and leaving 25 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7044.

Royal Bank of Canada first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $15K in Q3 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Royal Bank of Canada held 25 shares of Acrivon Therapeutics worth $0 as of Q1 2026.
Royal Bank of Canada sold 1,686 Acrivon Therapeutics shares in Q1 2026, an estimated $2.94K.
Acrivon Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7044 holding.
Royal Bank of Canada first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
Royal Bank of Canada's Acrivon Therapeutics position peaked at $15K in Q3 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.